These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39278067)

  • 1. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation.
    Hua M; Xiong F; Chong S; Zhang Z; Liu Q; Hou J; Zhang Z; Gu Z; Cui X; Cui Y; Xu L; Xiang Q
    Cancer Treat Rev; 2024 Nov; 130():102827. PubMed ID: 39278067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.
    Lin W; Zeng Y; Weng L; Yang J; Zhuang W
    BMC Pharmacol Toxicol; 2024 Aug; 25(1):47. PubMed ID: 39123221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.
    Gao S; Li Y; He Z; Zhu J; Liang D; Yang S; Mo J; Lam K; Yu X; Huang M; Wu J
    Expert Opin Drug Saf; 2023; 22(7):599-609. PubMed ID: 36794339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
    Xiao Z; Cao J; Wu S; Zhou T; Li C; Duan J; Yang Z; Xu F
    CNS Neurosci Ther; 2024 Jul; 30(7):e14862. PubMed ID: 39009505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data.
    Yan MM; Wu SS; Qi YP; Li ZR; Zhang Q; Zhao H; Zhong MK; Qiu XY
    Expert Opin Drug Saf; 2022 Feb; 21(2):277-283. PubMed ID: 34581647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system.
    Yan Y; Wu B; Wang L
    Expert Opin Drug Saf; 2024 Sep; 23(9):1191-1198. PubMed ID: 38482864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.
    Yu Z; Guan M; Liao X
    Clin Drug Investig; 2024 Oct; 44(10):789-798. PubMed ID: 39392584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
    Kappel C; Elliott MJ; Kumar V; Nadler MB; Desnoyers A; Amir E
    Sci Rep; 2024 Feb; 14(1):3129. PubMed ID: 38326452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
    Thein KZ; Htut TW; Ball S; Swarup S; Sultan A; Oo TH
    Breast Cancer Res Treat; 2020 Sep; 183(2):479-487. PubMed ID: 32647939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Murad B; Reis PCA; Deberaldini Marinho A; Marin Comini AC; Pinheiro Xavier D; Mella Soares Pessoa B; Raheem F; Ernst B; Mina LA; Batalini F
    JNCI Cancer Spectr; 2024 Sep; 8(5):. PubMed ID: 39254653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer.
    Zhao Q; Jiang M; Liu J; Zhang M; He M; Zhou S; Wang J; Mo H; Lan B; Yuan P; Zhang P; Ma F; Li Q; Xu B
    Cancer Biol Med; 2024 Sep; 21(10):934-50. PubMed ID: 39267478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Breast Cancer Res Treat; 2021 Feb; 186(1):219-227. PubMed ID: 33150548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
    Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
    Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
    Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.